Bone Biologics Corp Q1 2024 10-Q Filing

TL;DR

<b>Bone Biologics Corp reported a net loss of $1.1 million and $0 revenue for Q1 2024, with total assets of $1.48 million and no debt.</b>

AI Summary

Bone Biologics Corp (BBLGW) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Revenue for the three months ended March 31, 2024, was $0. Net loss for the three months ended March 31, 2024, was $1,107,000. Total assets as of March 31, 2024, were $1,482,000. Total debt as of March 31, 2024, was $0. The company reported $1,482,000 in total assets as of March 31, 2024.

Why It Matters

For investors and stakeholders tracking Bone Biologics Corp, this filing contains several important signals. The company generated no revenue in Q1 2024, indicating a lack of commercial sales or product adoption. The absence of debt suggests a reliance on equity financing or a focus on minimizing financial obligations.

Risk Assessment

Risk Level: — Bone Biologics Corp shows moderate risk based on this filing. The company reported zero revenue and a net loss of over $1 million in Q1 2024, with minimal assets and no debt, indicating significant financial challenges and a lack of commercial traction.

Analyst Insight

Bone Biologics Corp needs to demonstrate a clear path to revenue generation and profitability to attract investment and sustain operations.

Financial Highlights

total Assets

1482000

net Income

-1107000

Key Numbers

• $0 — Revenue (Q1 2024) (Three months ended March 31, 2024)
• $1,107,000 — Net Loss (Q1 2024) (Three months ended March 31, 2024)
• $1,482,000 — Total Assets (Mar 31, 2024) (As of March 31, 2024)
• $0 — Total Debt (Mar 31, 2024) (As of March 31, 2024)

Key Players & Entities

• Bone Biologics Corp (company) — FILER
• BBLGW (company) — tk
• 2024-03-31 (date) — CONFORMED PERIOD OF REPORT
• 2024-05-14 (date) — FILED AS OF DATE
• $1,107,000 (dollar_amount) — Net loss for the three months ended March 31, 2024
• $1,482,000 (dollar_amount) — Total assets as of March 31, 2024
• $0 (dollar_amount) — Total debt as of March 31, 2024
• $0 (dollar_amount) — Revenue for the three months ended March 31, 2024

FAQ

Industry Context

Bone Biologics Corp operates in the orthopedic, prosthetic & surgical appliances & supplies industry, focusing on bone regeneration technologies.

Regulatory Implications

The company is subject to standard SEC reporting requirements for public companies, including filing quarterly 10-Q reports.

What Investors Should Do

1. Analyze the company's strategy for revenue generation.
2. Investigate potential funding sources beyond equity.
3. Monitor future filings for signs of commercial progress.

Year-Over-Year Comparison

This filing is the Q1 2024 10-Q, providing an update on the company's financial status since the previous reporting period.

Key Financial Figures

• $0.001 — nge on which registered Common stock, $0.001 par value per share BBLG The Nasdaq

Filing Documents

• form10-q.htm (10-Q) — 658KB
• ex10-2.htm (EX-10.2) — 57KB
• ex10-3.htm (EX-10.3) — 19KB
• ex31-1.htm (EX-31.1) — 11KB
• ex31-2.htm (EX-31.2) — 11KB
• ex32-1.htm (EX-32.1) — 6KB
• ex32-2.htm (EX-32.2) — 6KB
• 0001493152-24-019271.txt (&nbsp;) — 4059KB
• bblg-20240331.xsd (EX-101.SCH) — 40KB
• bblg-20240331_cal.xml (EX-101.CAL) — 30KB
• bblg-20240331_def.xml (EX-101.DEF) — 132KB
• bblg-20240331_lab.xml (EX-101.LAB) — 342KB
• bblg-20240331_pre.xml (EX-101.PRE) — 243KB
• form10-q_htm.xml (XML) — 522KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION:

Financial Statements

Item 1. Financial Statements. F-1 Unaudited Condensed Consolidated Financial Statements Unaudited Condensed Consolidated Balance Sheets F-1 Unaudited Condensed Consolidated Statements of Operations F-2 Unaudited Condensed Consolidated Statements of Stockholders' Equity F-3 Unaudited Condensed Consolidated Statements of Cash Flows F-5 Notes to Unaudited Condensed Consolidated Financial Statements F-6

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 4

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 9

Controls and Procedures

Item 4. Controls and Procedures 9

– OTHER INFORMATION

PART II – OTHER INFORMATION: 10

Legal Proceedings

Item 1. Legal Proceedings 10

Risk Factors

Item 1A. Risk Factors 10

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 10

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 10

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 10

Other Information

Item 5. Other Information 10

Exhibits

Item 6. Exhibits 11

Signatures

Signatures 12 2 NOTE ON FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this "Form 10-Q") contains forward-looking statements. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. These forward-looking statements are based on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. For a more detailed listing of some of the risks and uncertainties facing the Company, please see our Current Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the Securities and Exchange Commission ("SEC") on February 21, 2024 and subsequent Quarterly Reports on Form 10-Q or other reports filed with the SEC. All expenditures, cash flows, business strategy and plans and objectives of management for future operations are forward-looking statements. The words "anticipate," "believe," "expect," "plan," "estimate," "project," "could," "may," "will," and similar expressions are intended to identify forward-looking statements. These statements include, among others, information regarding future operations, future capital expenditures, and future net cash flow. Such statements reflect our management's current views with respect to future events and financial performance and involve risks and uncertainties, including, without limitation, our ability to raise additional capital to fund our operations, inflation, rising interest rates, governmental responses there to and possible recession caus

forward-looking statements

forward-looking statements. Unless expressly indicated or the context requires otherwise, the terms "Company," "we," "us," and "our" in this document refer to Bone Biologics Corporation, a Delaware corporation and its wholly owned subsidiary as defined under the heading "Management's Discussion and Analysis" in this Form 10-Q. 3 PART I – FINANCIAL INFORMATION Item 1. Financial Statements. Bone Biologics Corporation Condensed Consolidated Balance Sheets March 31, 2024 December 31, 2023 Assets Current Assets Cash $ 3,227,634 $ 3,026,569 Advances on research and development contract services 328,844 328,844 Prepaid insurance 273,096 372,350 Prepaid expenses 10,000 10,000 Total current assets 3,839,574 3,737,763 Total assets $ 3,839,574 $ 3,737,763 Liabilities and Stockholders' Equity Current Liabilities Accounts payable and accrued expenses $ 146,186 $ 360,662 Accrued legal settlement - 414,989 Warrant liability 18,440 55,751 Total current liabilities 164,626 831,402 Total liabilities 164,626 831,402 Commitments and Contingencies - - Stockholders' Equity Preferred Stock, $ 0.001 par value per share; 20,000,000 shares authorized; none issued or outstanding at March 31, 2024 and December 31, 2023 - - Common stock, $ 0.001 par value per share; 100,000,000 shares authorized; 1,016,489 and 534,238 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 1,016 534 Additional paid-in capital 85,448,860 83,814,785 Accumulated deficit ( 81,774,928 ) ( 80,908,958 ) Total stockholders' equity 3,674,948 2,906,361 Total liabilities and stockholders' equity $ 3,839,574 $ 3,737,763 See accompanying notes to unaudited condensed consolidated financial statements. F-1 Bone Biologics Corporation Condensed Consolidated Statements of Operations Three Months Ended March 31, 2024 Three Months Ended March 31, 2023 Revenues $ - $ - Operating ex

View Full Filing

View this 10-Q filing on SEC EDGAR